OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing

NANTES, France, May 28, 2026 - OSE Immunotherapeutics SA, today announces the signature of a term sheet to implement a flexible bridge equity financing with IRIS Capital Investment (“IRIS”), known as SmartATM®. Under this financing, which is expected to be signed in the coming days, IRIS would commit to subscribe up to 4,000,000 new ordinary shares of the Company (ie. approximately 17.0% of OSE’s current share

capital), under certain conditions, at a 5% discount over a period of up to 24 months.

Download OSE Immunotherapeutics SA press release